A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors

NCT03539484 | Terminated Phase 1 Results FDA Drug

• 1 other identifier: BP40092
• Study Type: interventional
• Target: 26
• Locations: 4 countries
• Sites: 6

Brief Summary

This study was to determine the maximum-tolerated dose (MTD) and/or the optimal biological dose (OBD) as well as the optimal schedule for intravenous (IV) and subcutaneous (SC) administrations of RO7172508 as monotherapy, with or without obinutuzumab pre-treatment, in participants with locally advanced and/or metastatic carcinoembryonic antigen (CEA)-positive solid tumors who have progressed on standard of care (SOC) treatment, are intolerant to SOC, and/or are non-amenable to SOC. This study was conducted in two parts. Part I of the study consisted of an IV single participant cohort/multiple-ascending dose-escalation to evaluate the safety of RO7172508. Part II was a multiple participant cohort/multiple-ascending dose-escalation to define the MTD and/or OBD of RO7172508 administered as single agent, IV and/or SC, in participants with tumors that are expressing high as well as moderate/low-CEA. The study switched from Part I to Part II when the maximum planned dose for Part I was reached or the occurrence of a RO7172508-related Grade \>= 2 adverse event (AE) or dose-limiting toxicity (DLT) was observed, whichever comes first. The Sponsor may decide to switch from Part I to Part II in the absence of an observed RO7172508-related Grade \>= 2 toxicity or prior to maximum planned dose for Part I.

Conditions

Solid Tumors

Outcome Measures

Primary Outcomes (2)

• Number of Participants With Dose Limiting Toxicities (DLTs)

  Number of participants with DLTs.

  Up to approximately 12 months

• Percentage of Participants With Adverse Events

  Percentage of participants with adverse events.

  60 days after last dose of study treatment (up to approximately 12 months)

Secondary Outcomes (17)

• Maximum Concentration of RO7172508

  Cycle 1 following single dose administration of RO7172508

• Time of Maximum Concentration of RO7172508

  Cycle 1 following single dose administration of RO7172508

• Clearance or Apparent Clearance of RO7172508

  Cycle 1 following single dose administration of RO7172508

• Volume of Distribution at Steady State of RO7172508

  Cycle 1 following single dose administration of RO7172508

• Area Under the Plasma Concentration Time-Curve From Zero to the Last Measured Concentration (AUClast) of RO7172508

  Cycle 1 following single dose administration of RO7172508

Study Arms (3)

Part I: Single Participant Cohorts IV/MAD-Escalation

EXPERIMENTAL

Part I was a multiple-ascending dose-escalation in single participant cohorts. RO7172508 was administered intravenously once every 3 weeks (Q3W). The starting dose of RO7172508 was 65 microgram (mcg) and the maximum dose explored was 1.6 milligram (mg).

Drug: RO7172508; Drug: Tocilizumab

Part II: Multiple Participant Cohorts IV/MAD-Escalation

EXPERIMENTAL

Multiple ascending dose-escalation of IV-administered RO7172508 in multiple participant cohorts: The starting-dose for the initiation of the IV dose-escalation was determined by Part I and RO7172508 was initially given Q3W. Dose-escalation was undertaken based on safety until determination of the MTD or the highest safe dose if MTD is not reached. If on-target toxicity was reported in the first cycle of treatment, fractionated dosing may be implemented for the first cycle to improve tolerability.

Drug: RO7172508; Drug: Obinutuzumab; Drug: Tocilizumab

Part II: Multiple Participant Cohorts SC/MAD-Escalation (QW)

EXPERIMENTAL

Multiple ascending dose-escalation of SC-administered RO7172508 in multiple participant cohorts. These will be initiated once the IV schedule has shown RO7172508 preliminary clinical activity or the MTD has been established and is equal to or above 2 mg. The starting-dose and regimen once a week or once every 3 weeks (QW or Q3W) for SC administration will be proposed based on the evaluation of the safety and PK data observed following IV administration but will not exceed the highest safe dose tested in the IV Q3W dose escalation; a minimum dose of 2 mg is defined for a single SC administration. In addition, the QW SC starting-dose will not exceed one third of the IV MTD or of the highest safe IV dose tested. Dose escalation will continue based on safety until determination of the MTD or the planned maximum dose of 400 mg. If on-target toxicity is reported in the first cycle of treatment, fractionated dosing may be implemented for the first cycle to improve tolerability.

Drug: RO7172508; Drug: Obinutuzumab; Drug: Tocilizumab

Interventions

RO7172508 DRUG

RO7172508 was administered at a dose and as per the schedule specified in the respective arms.

Part I: Single Participant Cohorts IV/MAD-Escalation; Part II: Multiple Participant Cohorts IV/MAD-Escalation; Part II: Multiple Participant Cohorts SC/MAD-Escalation (QW)

Obinutuzumab DRUG

In the event obinutuzumab treatment is implemented, obinutuzumab will be administered either on Day-7 or on Day-7 and Day-6. If obinutuzumab is given only on one day, then the schedule for Day-7 should be followed including an end of infusion sample.

Part II: Multiple Participant Cohorts IV/MAD-Escalation; Part II: Multiple Participant Cohorts SC/MAD-Escalation (QW)

Tocilizumab DRUG

Tocilizumab was administered if required, for the management of severe CRS (cytokine release syndrome)

Part I: Single Participant Cohorts IV/MAD-Escalation; Part II: Multiple Participant Cohorts IV/MAD-Escalation; Part II: Multiple Participant Cohorts SC/MAD-Escalation (QW)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• For Part I: participants with locally advanced and/or metastatic solid tumor with confirmed cytoplasmic and/or membranous high CEA expression in tumor tissue is required. Participants must have progressed on a SOC therapy, be intolerant to SOC, and/or are non-amenable to SOC.
• For \<12 mg dose cohorts, serum CEA levels below a certain threshold is required as follows:
• For dose cohorts 65-159 microgram, a sCEA level of \< 22 ng/mL
• For dose cohorts 160-399 microgram, a sCEA level of \< 28 ng/mL
• For dose cohorts 400-799 microgram, a sCEA level of \< 44 ng/mL
• For dose cohorts 800-1599 microgram, a sCEA level of \< 70 ng/mL
• For the dose cohort of 1.6-3.1 milligram, a sCEA level of \< 123 ng/mL
• For the dose cohort of 3.2-6.3 milligram, an sCEA level of \< 229 ng/mL.
• For Part II, participants with locally advanced and/or metastatic solid tumor expressing cytoplasmic and/or membranous high-CEA or moderate/low-CEA on archival material, who have progressed on a SOC therapy, are intolerant to SOC, and/or are non-amenable to SOC. Participants must have a lesion amenable to biopsy (except participants with NSCLC, which may be enrolled with archival tissue available only). For participants with colorectal cancer (CRC) only, the CEA assessment by immunohistochemistry should be performed but the result is not required to enroll the participant.
• Radiologically measurable disease according to RECIST v1.1.
• Life expectancy of \>= 12 weeks
• Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1.
• All acute toxic effects of any prior radiotherapy, chemotherapy, or surgical procedure must have resolved to Grade \<= 1 or returned to baseline except alopecia (any grade) and Grade 2 peripheral neuropathy.
• Adequate hematological, liver, renal, and lung function
• For women: agree to remain abstinent or use two contraceptive methods that result in a failure rate of \<1% per year from screening until 2 months after the last dose of RO7172508 and have a negative pregnancy test within one week prior to the first study treatment administration

You may not qualify if:

• History or clinical evidence of central nervous system (CNS) primary tumors or metastases unless they have been previously treated, are asymptomatic, and have had no requirement for steroids or enzyme-inducing anticonvulsants in the last 14 days before screening.
• Non-irradiated lesions \> 2 cm at critical sites where tumor swelling induced by RO7172508 is expected to lead to significant complications.
• Another invasive malignancy in the last 2 years
• Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results or contraindicate the use of an investigational drug.
• Uncontrolled hypertension, unstable angina, congestive heart failure, serious cardiac arrhythmia that requires treatment with the exceptions of atrial fibrillation and paroxysmal supraventricular tachycardia, and history of myocardial infarction within 6 months of enrollment.
• Active or uncontrolled infections.
• Known hepatitis B or C
• Major surgery or significant traumatic injury \< 28 days prior to the first RO7172508 administration or anticipation of the need for major surgery during study treatment.
• Known HIV
• Positive test results for HBV infection, HBcAb indicating an active viral infection and positive test results for HCV.
• Participants positive for HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA).
• History of progressive multifocal leukoencephalopathy.
• Active TB requiring treatment within 3 years prior to baseline.
• Latent TB diagnosed during Screening.
• Positive test results for human T-lymphotropic virus 1

Sponsors & Collaborators

• Hoffmann-La Roche: lead

Study Sites (6)

Cliniques Universitaires St-Luc

Brussels, 1200, Belgium

Location

Princess Margaret Cancer Center

Toronto, Ontario, M5G 1Z5, Canada

Location

Rigshospitalet; Onkologisk Klinik

København Ø, 2100, Denmark

Location

Clinica Universitaria de Navarra

Pamplona, Navarre, 31008, Spain

Location

Hospital Univ Vall d'Hebron; Servicio de Oncologia

Barcelona, 08035, Spain

Location

START Madrid. Centro Integral Oncologico Clara Campal; CIOCC

Madrid, 28050, Spain

Location

MeSH Terms

Interventions

obinutuzumab; tocilizumab

Limitations and Caveats

RO7172508 SC not initiated; max tolerated dose IV below starting dose for SC. Study terminated due to change in benefit-risk ratio, driven by high incidence GI toxicity in absence of clinically significant anti-tumor efficacy at dose levels tested.

Results Point of Contact

• Title: Medical Communications
• Organization: Hoffmann-La Roche

genentech@druginfo.com

800-821-8590

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 19, 2018
• First Posted: May 29, 2018
• Study Start: July 4, 2018
• Primary Completion: July 22, 2019
• Study Completion: July 22, 2019
• Last Updated: September 3, 2020
• Results First Posted: September 3, 2020

Record last verified: 2020-08

Locations

BE (1); CA (1); ES (3); DK (1)